289 Call for tenders SANTE2020C3049 for the development production priority purchasing options and supply of COVID 19 Ares 2021 312310 redacted s.pdf
1 PDF-Seiten
Quelle öffnen →Start / Quellenregister
Dokumentation
Quellenregister
1852 Belegkennungen mit Originaladressen und Fundstellen. Historische Fassungen werden nach ihrem eigenen Datum geführt.
Die Originale und ihre Belegkennungen.
29 Email Agenda SB 04 September Redacted s.pdf
2 PDF-Seiten
Quelle öffnen →290 Tender submission see 8 below entries submission in 8 emails Ares 2021 399673 redacted s.pdf
2 PDF-Seiten
Quelle öffnen →299 SANTE2020C3049 Notification Letter Call for tenders for the development production priority purchasing options Ares 2020 6962203 redacted s.pdf
1 PDF-Seiten
Quelle öffnen →30 SB Minutes 4 September 2021 Redacted s.pdf
3 PDF-Seiten
Quelle öffnen →300 Notification letter SANTE2020C3049 Development production priority purchasing options and supply of COVID 19 Ares 2021 340610 redacted s.pdf
1 PDF-Seiten
Quelle öffnen →301 questionnaire CureVac 12052020 pdf 1.pdf
5 PDF-Seiten
Quelle öffnen →302 skype meeting with CureVac vaccine 07 05 2020 Redacted s.pdf
3 PDF-Seiten
Quelle öffnen →302 skype meeting with CureVac vaccine 07 05 2020.pdf
3 PDF-Seiten
Quelle öffnen →303 APA with Sanofi and GSK 18 09 2020.pdf
53 PDF-Seiten
Quelle öffnen →304 Call for tenders SANTE2020C3042 for the development production priority purchasing options and supply of COVID 19 Ares 2021 312411 redacted s.pdf
1 PDF-Seiten
Quelle öffnen →306 SANTE2020C3042 Notification Letter Call for tenders for the development production priority purchasing options Ares 2020 4819456 redacted s.pdf
1 PDF-Seiten
Quelle öffnen →307 Notification letter SANTE2020C3042 Development production priority purchasing options and supply of COVID 19 Ares 2021 340742 redacted s.pdf
1 PDF-Seiten
Quelle öffnen →308 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 27 08 20 Sanofi Redacted s.pdf
2 PDF-Seiten
Quelle öffnen →309 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 27 08 2020 App Redacted s.pdf
2 PDF-Seiten
Quelle öffnen →31 1 Agenda SB Minutes 11 September 2020 Redacted s.pdf
1 PDF-Seiten
Quelle öffnen →31 1 Agenda SB Minutes 11 September 2020 Redacted s.pdf
1 PDF-Seiten
Quelle öffnen →31 Email SB Agenda 11 September 2020 Redacted s.pdf
2 PDF-Seiten
Quelle öffnen →31 Email SB Agenda 11 September 2020 Redacted s.pdf
2 PDF-Seiten
Quelle öffnen →310 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 03 09 20 Redacted s.pdf
1 PDF-Seiten
Quelle öffnen →311 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 04 09 20 Redacted s.pdf
2 PDF-Seiten
Quelle öffnen →313 Email 6 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 10 09 20 Redacted s.pdf
9 PDF-Seiten
Quelle öffnen →314 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 11 09 20 Sanofi Internal Redacted s.pdf
1 PDF-Seiten
Quelle öffnen →315 Email 8 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 11 09 20 2 Redacted s.pdf
10 PDF-Seiten
Quelle öffnen →316 Draft APA negotiated between Sanofi GSK and the Evaluation Committee 11 09 20 3 Sanofi Internal Redacted s.pdf
1 PDF-Seiten
Quelle öffnen →317 Sanofi 10 Draft APA negotiated between SanofiGSK and the Evaluation Committee 14 09 20 Redacted s.pdf
13 PDF-Seiten
Quelle öffnen →318 and 319 Scan of a signed version of the APA sent to Sanofi GSK 25 09 20 Redacted s.pdf
4 PDF-Seiten
Quelle öffnen →320 Sanofi GSK COVID19 vaccine Progress report 26 10 20 Redacted s.pdf
1 PDF-Seiten
Quelle öffnen →321 1 Sanofi GSK proposed options on post approval studies 08 09 20 Redacted s.pdf
1 PDF-Seiten
Quelle öffnen →321 Sanofi GSK proposed options on post approval studies 08 09 20 Redacted s.pdf
2 PDF-Seiten
Quelle öffnen →322 Ares 2021 745642 Sanofi GSK Scientific technical presentation Sanofi GSK 09 09 20 Redacted s.pdf
4 PDF-Seiten
Quelle öffnen →323 Summary of the meeting with Sanofi 26 October 1200 1245 pm via WebEx Redacted s.pdf
2 PDF-Seiten
Quelle öffnen →324 1 Sanofi response to the questionnaire 19 05 20 Redacted s.pdf
14 PDF-Seiten
Quelle öffnen →324 Sanofi response to the questionnaire 19 05 20 Email Redacted s.pdf
2 PDF-Seiten
Quelle öffnen →325 GSK response to the questionnaire 21 05 20 Redacted s.pdf
8 PDF-Seiten
Quelle öffnen →326 Draft term sheet discussed with Sanofi GSK at the JNT during the exploratory talks 12 06 20 Redacted s.pdf
1 PDF-Seiten
Quelle öffnen →